These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

465 related items for PubMed ID: 25676581

  • 1. Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1.
    Kumari R, Nguyen MH.
    Expert Opin Pharmacother; 2015 Apr; 16(5):739-48. PubMed ID: 25676581
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.
    Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Subramanian GM, Symonds WT, McHutchison JG, Pang PS.
    Gastroenterology; 2014 Mar; 146(3):736-743.e1. PubMed ID: 24262278
    [Abstract] [Full Text] [Related]

  • 3. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
    Mizokami M, Dvory-Sobol H, Izumi N, Nishiguchi S, Doehle B, Svarovskaia ES, De-Oertel S, Knox S, Brainard DM, Miller MD, Mo H, Sakamoto N, Takehara T, Omata M.
    J Viral Hepat; 2016 Oct; 23(10):780-8. PubMed ID: 27196675
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
    Moser S, Kozbial K, Laferl H, Schütz A, Reiberger T, Schwabl P, Gutic E, Schwanke C, Schubert R, Luhn J, Lang T, Schleicher M, Steindl-Munda P, Haltmayer H, Ferenci P, Gschwantler M.
    Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):291-295. PubMed ID: 29120906
    [Abstract] [Full Text] [Related]

  • 5. Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam.
    Thu Thuy PT, Bunchorntavakul C, Tan Dat H, Palecki J, Reddy KR.
    Antivir Ther; 2018 Mar; 23(5):415-423. PubMed ID: 29303482
    [Abstract] [Full Text] [Related]

  • 6. Perspectives of fixed daily dose of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C.
    Floreani A.
    Expert Opin Pharmacother; 2015 Apr; 16(6):801-4. PubMed ID: 25728621
    [Abstract] [Full Text] [Related]

  • 7. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, Mathurin P, Tran A, Larrey DG, Ratziu V, Alric L, Hyland RH, Jiang D, Doehle B, Pang PS, Symonds WT, Subramanian GM, McHutchison JG, Marcellin P, Habersetzer F, Guyader D, Grangé JD, Loustaud-Ratti V, Serfaty L, Metivier S, Leroy V, Abergel A, Pol S.
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [Abstract] [Full Text] [Related]

  • 8. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
    Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P, ION-2 Investigators.
    N Engl J Med; 2014 Apr 17; 370(16):1483-93. PubMed ID: 24725238
    [Abstract] [Full Text] [Related]

  • 9. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
    Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, Fried MW, Terrault NA, O'Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J, Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N, SOLAR-1 Investigators.
    Gastroenterology; 2015 Sep 17; 149(3):649-59. PubMed ID: 25985734
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
    Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, Kuo A, Lok AS, Shiffman ML, Ben Ari Z, Akushevich L, Vainorius M, Sulkowski MS, Fried MW, Nelson DR, HCV-TARGET Study Group.
    Gastroenterology; 2016 Dec 17; 151(6):1131-1140.e5. PubMed ID: 27565882
    [Abstract] [Full Text] [Related]

  • 11. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    Buggisch P, Wursthorn K, Stoehr A, Atanasov PK, Supiot R, Lee J, Ting J, Petersen J.
    PLoS One; 2019 Dec 17; 14(4):e0214795. PubMed ID: 30946776
    [Abstract] [Full Text] [Related]

  • 12. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
    Tam E, Luetkemeyer AF, Mantry PS, Satapathy SK, Ghali P, Kang M, Haubrich R, Shen X, Ni L, Camus G, Copans A, Rossaro L, Guyer B, Brown RS, RESCUE and ACTG A5348 study investigators.
    Liver Int; 2018 Jun 17; 38(6):1010-1021. PubMed ID: 29091342
    [Abstract] [Full Text] [Related]

  • 13. NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
    Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, Takahashi K, Kawano A, Azuma K, Satoh T, Nakamuta M, Koyanagi T, Kato M, Shimoda S, Kajiwara E, Hayashi J, Kyushu University Liver Disease Study (KULDS) Group.
    J Gastroenterol; 2017 Jul 17; 52(7):845-854. PubMed ID: 27913920
    [Abstract] [Full Text] [Related]

  • 14. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
    Lv DD, Wang ML, Chen EQ, Wu DB, Tao YC, Zhang DM, Tang H.
    Eur J Gastroenterol Hepatol; 2019 Mar 17; 31(3):382-388. PubMed ID: 30383554
    [Abstract] [Full Text] [Related]

  • 15. Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients.
    Babatin MA, AlGhamdi AS, Assiri AM, AlBiladi H, AlOthmani HS, Mogharbel MH, Mahallawi W, Asselah T, Sanai FM.
    Saudi J Gastroenterol; 2019 Mar 17; 25(1):55-60. PubMed ID: 30117490
    [Abstract] [Full Text] [Related]

  • 16. Eight-Week Outcomes of Ledipasvir/Sofosbuvir in Noncirrhotic Treatment-Naive Patients with Hepatitis C: Analysis of Pharmacy-Based Data.
    Andres J, Lott S, Qureshi K.
    J Manag Care Spec Pharm; 2018 Jan 17; 24(1):23-28. PubMed ID: 29290174
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
    Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC.
    Aliment Pharmacol Ther; 2015 Mar 17; 41(6):544-63. PubMed ID: 25619871
    [Abstract] [Full Text] [Related]

  • 19. Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
    Aqel B, Leise M, Vargas HE, Watt KD, Keaveny AP, Zhang N, Zhang N, Pungpapong S.
    Ann Hepatol; 2018 Aug 24; 17(5):815-821. PubMed ID: 30145562
    [Abstract] [Full Text] [Related]

  • 20. Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital.
    Del Rio-Valencia JC, Asensi-Diez R, Madera-Pajin R, Yunquera-Romero L, Muñoz-Castillo I.
    Rev Esp Quimioter; 2018 Feb 24; 31(1):35-42. PubMed ID: 29376623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.